ARS Pharmaceuticals, Inc (SPRY) — Capital Reinvestment Ratio
ARS Pharmaceuticals, Inc (SPRY) has a Capital Reinvestment Ratio of 0.01x as of December 2024, meaning it reinvests 0% of its operating cash flow ($42.00 Million) in capital expenditures ($302.00K). Check SPRY tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
ARS Pharmaceuticals, Inc Capital Reinvestment Ratio (2020–2024)
This chart tracks ARS Pharmaceuticals, Inc's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see SPRY cash flow metrics.
Annual Capital Reinvestment Ratio for ARS Pharmaceuticals, Inc (2020–2024)
Year-by-year Capital Reinvestment Ratio for ARS Pharmaceuticals, Inc from 2020 to 2024. See SPRY free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.04x | $13.55 Million | $563.00K | ▼ -58.9% |
| 2020 | 0.10x | $9.07 Million | $917.00K | — |